Multicenter phase II trial of Camrelizumab combined with Apatinib and Eribulin in heavily pretreated patients with advanced triple-negative breast cancer

Multicenter phase II trial of Camrelizumab combined with Apatinib and Eribulin in heavily pretreated patients with advanced triple-negative breast cancer

Therapeutic options for patients with triple-negative breast cancer (TNBC) in later-line setting are limited. Here the authors report the results of a phase 2 clinical trial to evaluate efficacy and safety of the combination of camrelizumab (anti-PD1), apatinib (VEGFR2 inhibitor), and eribulin in pa...

Full description

Bibliographic Details
Main Authors: Jieqiong Liu, Ying Wang, Zhenluan Tian, Ying Lin, Hengyu Li, Zhaowen Zhu, Qiang Liu, Shicheng Su, Yinduo Zeng, Weijuan Jia, Yaping Yang, Shengqiang Xu, Herui Yao, Wen Jiang, Erwei Song
Format: Article
Language:English
Published: Nature Portfolio 2022-05-01
Series:Nature Communications
Online Access:https://doi.org/10.1038/s41467-022-30569-0

Similar Items

Similar Items